Aurinia worth ‘keeping closer eye on’ after settlement, Dealreporter says

After Aurinia Pharmaceuticals (AUPH) announced a patent settlement with India’s Sun Pharmaceuticals regarding lead asset Lupkynis, Dealreporter said in a flash note to its subscribers that it will "be keeping a closer eye" on Aurinia for signs of momentum toward a sale with this patent overhang lifted. The M&A focused publication noted, according to contacts, that Bloomberg reported in late 2021 that Aurinia had received a takeover approach from Bristol-Myers (BMY), but a sale never materialized.